Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma.

Eur J Clin Microbiol Infect Dis. 1998 Jan;17(1):58-60. Unique Identifier : AIDSLINE MED/98171139
Reiser M; Bruns C; Hartmann P; Salzberger B; Diehl V; Fatkenheuer G; Medizinische Klinik I, University Hospital, Cologne, Germany.

Abstract: Raynaud's phenomenon is a common vascular side effect of chemotherapy drug regimens. Chemotherapy-induced Raynaud's phenomenon leading to acral gangrene has rarely been reported. In this report, one patient who developed gangrene after bleomycin and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. Because the combination of bleomycin and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. The literature is reviewed, and clinical symptoms, pathophysiology, and treatment options are discussed.
Keywords: *Antineoplastic Agents, Combined/ADVERSE EFFECTS *AIDS-Related Opportunistic Infections/DRUG THERAPY *Gangrene/CHEMICALLY INDUCED *Raynaud's Disease/CHEMICALLY INDUCED *Sarcoma, Kaposi/DRUG THERAPY

KWDantineoplasticagents,combined/adverseeffectsKWDaids-relatedopportunisticinfections/drugtherapyKWDgangrene/chemicallyinducedKWDraynaud'sdisease/chemicallyinducedKWDsarcoma,kaposi/drugtherapy
980730
M9871317

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .